Market Views – Page 32 – media

Cardiologs raises $6m in Series A to support ECG Analysis Platform

Cardiologs Technologies said this week it raised $6.4 million in a Series A round of financing to support accelerated commercialization of its Cardiologs ECG Analysis Platform in the US and Europe.
- Source: Massdevice
- 478
- October 10, 2017
Cardiologs Market Views Series
Big Pharma Gets Boost as China Speeds Up New Drug Approvals

For decades, Chinese patients have struggled to gain access to cutting-edge medicines thanks to bureaucratic delays that have hamstrung drug development. Now a sweeping government overhaul of drug approvals is poised to change that.
- Source: bloomberg
- 518
- October 10, 2017
Chinese drug approval Market Views
Merck Discontinues MK-3682B and MK-3682C Development Programs

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection.
- Source: Mrknewsroom
- 600
- September 30, 2017
chronic hepatitis C virus (HCV) infection Market Views Merck
Two Scientists Nab Another $20 Million for Their CRISPR Biotech Eligo Bioscience

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge. This comes just months after Eligo was selected as one of the 30 Most Innovative Companies in 2017 by the World Economic Forum. This funding will enable Eligo to strengthen its biotherapeutic platform, begin clinical trials for its lead indication and extensively grow its international team of scientists, engineers, and executives.
- Source: Biospace
- 535
- September 29, 2017
Market Views microbiome Series
Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China

Amgen and Simcere Pharmaceutical Group today announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology.
- Source: Amgen
- 649
- September 28, 2017
biosimilar inflammation Market Views oncology
J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

A couple of months after posting positive late-stage data for its quadruplet-in-one-pill for quelling HIV, J&J says it’s filed a marketing application with the FDA ahead of a planned marketing campaign.
- Source: Endpts
- 563
- September 27, 2017
FDA Gilead GSK HIV J&J Market Views
FEops closes €6m Series B financing

FEops, a leader in personalized computer modeling for structural heart interventions, announced today that it has secured a 6 million euros investment, led by Valiance, and joined by existing investors Capricorn and PMV.
- Source: medicaldevices-business-review
- 632
- September 26, 2017
heart investment Market Views Series
Centinel Spine acquires Prodisc assets from J&J’s DePuy Synthes

Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report.
- Source: Massdevice
- 677
- September 20, 2017
acquisition Market Views Prodisc
LifeMine Therapeutics combines AI, drug discovery & microbes with $55m launch

Backed by the likes of Google and Merck (NYSE:MRK), Cambridge, Mass.-based LifeMine Therapeutics launched today by closing a $55 million Series A round.
- Source: Drugdeliverybusiness
- 466
- September 19, 2017
Market Views Merck Series
Boehringer collaborates with Gubra to develop next generation obesity treatments

Germany based Boehringer Ingelheim has committed up to €250 million ($300 million) to work with Gubra on obesity treatments. As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
- Source: Biospectrumasia
- 492
- September 14, 2017
cardiometabolic Market Views obesity

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.